Yonsei University

Radiomics in Rectal Cancer: A Powerful Tool for Diagnosis, Treatment Response Evaluation, and Prognosis Prediction

4 months ago

• Radiomics, an advanced computational approach that extracts quantitative features from medical images, is revolutionizing rectal cancer management by providing more accurate tumor staging and treatment response prediction than conventional imaging methods. • Recent studies demonstrate radiomics' effectiveness in predicting lymph node metastasis, distant metastasis, and pathological complete response to neoadjuvant therapy, with multimodal approaches combining CT, MRI, and ultrasound showing the highest predictive accuracy. • The integration of radiomics with deep learning algorithms and molecular markers represents the future direction of research, potentially enabling more personalized treatment strategies and improved patient outcomes in rectal cancer care.

Handok's Open Innovation Strategy Drives New Drug Development and Global Expansion

6 months ago

• Handok Pharmaceutical has embraced open innovation since 2007, collaborating with companies like Genexine and ABL Bio to expedite new drug R&D. • The company's strategic investments, including HDB001A for biliary tract cancer, have led to Phase 2/3 trials approved by the FDA, with top-line results expected in early 2025. • Handok is also focusing on digital transformation and AI to boost productivity in clinical trials and new drug development, aiming to launch multiple new products. • With its 70th anniversary, Handok aims to solidify its position as a 'best partner' in the Korean market and expand into Southeast Asia.

Niraparib Shows Promise in Extending Progression-Free Survival in Epithelial Ovarian Cancer

6 months ago

• Niraparib monotherapy extends real-world progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC). • Patients with homologous recombination-deficient (HRd) tumors, particularly those with BRCA-mutated tumors, experienced longer rwPFS and rwTTNT. • Niraparib demonstrates clinical benefit in stage III EOC patients with no visible residual disease (NVRD) after primary cytoreductive surgery (PCS). • Niraparib stands out among PARP inhibitors for its broad frontline maintenance therapy approval in EOC, regardless of BRCA mutation or HRD status.